{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:24:26Z","timestamp":1786983866328,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier","isbn-type":[{"value":"9780443313967","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.enz.2025.06.003","type":"book-chapter","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:49:43Z","timestamp":1754452183000},"page":"151-182","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis C virus (HCV) proteases: structure, function and inhibition strategies"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.enz.2025.06.003_bib0001","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/bs.enz.2025.06.003_bib0002","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0003","unstructured":"World Health Organization Hepatitis C available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (Accessed March 13, 2025)."},{"key":"10.1016\/bs.enz.2025.06.003_bib0004","article-title":"The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019","volume":"11","author":"Yang","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/bs.enz.2025.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/microorganisms12061035","article-title":"Contemporary insights into hepatitis C virus: a comprehensive review","volume":"12","author":"Sallam","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/bs.enz.2025.06.003_bib0006","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0007","first-page":"12","article-title":"A tale of two viruses: immunological insights into HCV\/HIV coinfection","author":"Gobran","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0008","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/jvh.13861","article-title":"Mortality and morbidity related to hepatitis C virus infection in hospitalized adults\u2014A propensity score matched analysis","volume":"30","author":"Hovaguimian","year":"2023","journal-title":"J. Viral Hepat."},{"key":"10.1016\/bs.enz.2025.06.003_bib0009","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/livers4020013","article-title":"The epidemiology of chronic hepatitis C: where we are now","volume":"4","author":"Stasi","year":"2024","journal-title":"Livers"},{"key":"10.1016\/bs.enz.2025.06.003_bib0010","unstructured":"World Health Organization Global health sector strategies 2022-2030 https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/strategies\/global-health-sector-strategies (Accessed March 13, 2025)."},{"key":"10.1016\/bs.enz.2025.06.003_bib0011","doi-asserted-by":"crossref","first-page":"e1254","DOI":"10.1093\/infdis\/jiae253","article-title":"Identification of 2 novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals","volume":"230","author":"Mbisa","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/bs.enz.2025.06.003_bib0012","doi-asserted-by":"crossref","first-page":"ofz076","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 novel hepatitis C virus subtypes\u2014Further expanding HCV classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/bs.enz.2025.06.003_bib0013","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/jvi.66.5.3225-3229.1992","article-title":"Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution","volume":"66","author":"Martell","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0014","first-page":"541","article-title":"Virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges","volume":"31","author":"Shahnazarian","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0015","doi-asserted-by":"crossref","first-page":"e5504","DOI":"10.1590\/1414-431x20165504","article-title":"Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents","volume":"49","author":"Zanaga","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/bs.enz.2025.06.003_bib0016","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/v13081580","article-title":"SHARED: an international collaboration to unravel hepatitis C resistance","volume":"13","author":"Howe","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.003_bib0017","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/flgastro-2022-102373","article-title":"Hepatitis C: recent advances and practical management","volume":"14","author":"Kane","year":"2023","journal-title":"Front. Gastroenterol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/ng.453","article-title":"Interferon-alfa, Interferon-\u03bb and Hepatitis C","volume":"41","author":"O\u2019Brien","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.enz.2025.06.003_bib0019","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2025.06.003_bib0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2010.01.011","article-title":"Characterization of ribavirin uptake systems in human hepatocytes","volume":"52","author":"Fukuchi","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0021","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/bs.enz.2025.06.003_bib0022","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"10.1016\/bs.enz.2025.06.003_bib0023","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3855\/jidc.14485","article-title":"Antivirals against HCV infection: the story thus far","volume":"16","author":"Irekeola","year":"2022","journal-title":"J. Infect. Develop. Count."},{"key":"10.1016\/bs.enz.2025.06.003_bib0024","article-title":"Price of a hepatitis C cure: cost of production and current prices for direct-acting antivirals in 50 countries","volume":"6","author":"Barber","year":"2020","journal-title":"J. Virus Erad."},{"key":"10.1016\/bs.enz.2025.06.003_bib0025","unstructured":"Unitaid, World Health Organization. Technology and Market Landscape for Hepatitis C Medicines, Unitaid, World Health Organization, Switzerland, Vernier, 2017."},{"key":"10.1016\/bs.enz.2025.06.003_bib0026","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3390\/v14030505","article-title":"Hepatitis C: standard of treatment and what to do for global elimination","volume":"14","author":"Di Marco","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.003_bib0027","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3350\/cmh.2020.0230","article-title":"Current and future strategies for the treatment of chronic hepatitis C","volume":"27","author":"Alshuwaykh","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0028","series-title":"Hepatitis C Virus: From Molecular Virology to Antiviral Therapy","first-page":"143","article-title":"Hepatitis C virus RNA translation","volume":"369","author":"Niepmann","year":"2013"},{"key":"10.1016\/bs.enz.2025.06.003_bib0029","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrmicro3506","article-title":"The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA","volume":"13","author":"Li","year":"2015","journal-title":"Nat. Rev. Micro."},{"key":"10.1016\/bs.enz.2025.06.003_bib0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/bs.enz.2025.06.003_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.enz.2025.06.003_bib0032","series-title":"Hepatitis C Viruses: Genomes and Molecular Biology","article-title":"HCV NS2\/3 protease","author":"Welbourn","year":"2006"},{"key":"10.1016\/bs.enz.2025.06.003_bib0033","doi-asserted-by":"crossref","first-page":"29604","DOI":"10.1074\/jbc.M505019200","article-title":"Hepatitis C virus NS2\/3 processing is required for NS3 stability and viral RNA replication *","volume":"280","author":"Welbourn","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0034","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nature04975","article-title":"Structure of the catalytic domain of the hepatitis C virus NS2-3 protease","volume":"442","author":"Lorenz","year":"2006","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2025.06.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006863","article-title":"NS2 proteases from hepatitis C virus and related hepaciviruses share composite active sites and previously unrecognized intrinsic proteolytic activities","volume":"14","author":"Boukadida","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.enz.2025.06.003_bib0036","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3390\/v2081635","article-title":"The hepatitis C virus nonstructural protein 2 (NS2): an up-and-coming antiviral drug target","volume":"2","author":"Lorenz","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.003_bib0037","doi-asserted-by":"crossref","first-page":"28546","DOI":"10.1074\/jbc.M803981200","article-title":"Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly","volume":"283","author":"Jirasko","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0038","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/JVI.01070-10","article-title":"Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins","volume":"85","author":"Ma","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0039","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)81350-1","article-title":"The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site","volume":"87","author":"Love","year":"1996","journal-title":"Cell"},{"key":"10.1016\/bs.enz.2025.06.003_bib0040","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1128\/JVI.75.20.9939-9946.2001","article-title":"Characterization of the hepatitis C virus NS2\/3 processing reaction by using a purified precursor protein","volume":"75","author":"Pallaoro","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0041","series-title":"Fundamental Viriology","article-title":"Flaviviridae: the viruses and their replication","author":"Lindenbach","year":"2001"},{"key":"10.1016\/bs.enz.2025.06.003_bib0042","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1073\/pnas.0810950106","article-title":"Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3","volume":"106","author":"Schregel","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/bs.enz.2025.06.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010644","article-title":"Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity","volume":"18","author":"Isken","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.enz.2025.06.003_bib0044","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2217\/fvl.09.29","article-title":"HCV NS2\/3 protease: a future antiviral drug target?","volume":"4","author":"Welbourn","year":"2009","journal-title":"Future Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0045","doi-asserted-by":"crossref","first-page":"34511","DOI":"10.1074\/jbc.274.49.34511","article-title":"Inhibition of hepatitis C virus NS2\/3 processing by NS4A peptides","volume":"274","author":"Darke","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0046","doi-asserted-by":"crossref","first-page":"46678","DOI":"10.1074\/jbc.M108266200","article-title":"In vitro characterization of a purified NS2\/3 protease variant of hepatitis C virus","volume":"276","author":"Thibeault","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0047","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/108705710200700208","article-title":"A collaborative screening program for the discovery of inhibitors of HCV NS2\/3 cis-cleaving protease activity","volume":"7","author":"Whitney","year":"2002","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/bs.enz.2025.06.003_bib0048","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.241510898","article-title":"Host cell factor requirement for hepatitis C virus enzyme maturation","volume":"98","author":"Waxman","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/bs.enz.2025.06.003_bib0049","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.antiviral.2015.10.001","article-title":"Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease","volume":"124","author":"Shaw","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/bs.enz.2025.06.003_bib0050","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0042-6822(87)90250-9","article-title":"Differences in virus-induced polypeptides in cells infected by cytopathic and noncytopathic biotypes of bovine virus diarrhea-mucosal disease virus","volume":"158","author":"Donis","year":"1987","journal-title":"Virology"},{"key":"10.1016\/bs.enz.2025.06.003_bib0051","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01313724","article-title":"Variation in the intracellular polypeptide profiles from different isolates of bovine virus diarrhoea virus","volume":"94","author":"Pocock","year":"1987","journal-title":"Arch. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0052","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1348-0421.2008.00013.x","article-title":"Cleavage of the NS2-3 protein in the cells of cattle persistently infected with non-cytopathogenic bovine viral diarrhea virus","volume":"52","author":"Kameyama","year":"2008","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0053","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/JVI.78.5.2414-2425.2004","article-title":"Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus","volume":"78","author":"Agapov","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0054","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/bs.enz.2025.06.003_bib0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/bs.enz.2025.06.003_bib0056","series-title":"Hepatitis C Viruses: Genomes and Molecular Biology","article-title":"HCV NS3-4A serine protease","author":"Lin","year":"2006"},{"key":"10.1016\/bs.enz.2025.06.003_bib0057","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","article-title":"Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus","volume":"18","author":"Morikawa","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/bs.enz.2025.06.003_bib0058","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/jvi.68.6.3753-3760.1994","article-title":"Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins","volume":"68","author":"Failla","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0059","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1128\/jvi.69.4.2534-2539.1995","article-title":"NS3-4A of hepatitis C virus is a chymotrypsin-like protease","volume":"69","author":"Hahm","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/467869","article-title":"Hepatitis C virus NS3 inhibitors: current and future perspectives","volume":"2013","author":"Salam","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/bs.enz.2025.06.003_bib0061","doi-asserted-by":"crossref","first-page":"22725","DOI":"10.1074\/jbc.R110.125294","article-title":"hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target","volume":"285","author":"Raney","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0062","series-title":"The Hepatitis C Viruses","first-page":"149","article-title":"Structure and function of the hepatitis C virus NS3-NS4A serine proteinase","author":"De Francesco","year":"2000"},{"key":"10.1016\/bs.enz.2025.06.003_bib0063","first-page":"22","article-title":"The discovery and development of boceprevir&colon, a novel, first‐ generation inhibitor of the hepatitis C virus NS3/4A serine protease","volume":"1","author":"Howe","year":"2013","journal-title":"J. Clin. Translat. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0064","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.9b00675","article-title":"Molecular and structural mechanism of pan-genotypic HCV NS3\/4A protease inhibition by glecaprevir","volume":"15","author":"Timm","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0067","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","article-title":"SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells","volume":"50","author":"Malcolm","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.enz.2025.06.003_bib0068","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.enz.2025.06.003_bib0069","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/jm401507s","article-title":"Discovery and development of simeprevir (TMC435), a HCV NS3\/4A protease inhibitor","volume":"57","author":"Rosenquist","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0070","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.enz.2025.06.003_bib0071","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/ml300017p","article-title":"Discovery of MK-5172, a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"3","author":"Harper","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.003_bib0072","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1021\/ml400466p","article-title":"Novel quinoline-based P2\u2013P4 macrocyclic derivatives as pan-genotypic HCV NS3\/4a protease inhibitors","volume":"5","author":"Shah","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.003_bib0073","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/j.bmcl.2019.03.037","article-title":"Discovery of the pan-genotypic hepatitis C virus NS3\/4A protease inhibitor voxilaprevir (GS-9857): a component of Vosevi\u00ae","volume":"29","author":"Taylor","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.enz.2025.06.003_bib0074","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.1021\/acs.jmedchem.1c00554","article-title":"Discovery of quinoxaline-based P1\u2013P3 macrocyclic NS3\/4A protease inhibitors with potent activity against drug-resistant hepatitis C virus variants","volume":"64","author":"Nageswara Rao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0066","unstructured":"U.S. Food & Drug Administraton, First oral pan-genotypic HCV drugs approved for children as young as 3 years, AAP News [internet], 2021 Nov. 1 [cited 2025 Apr 22]; [about 2 p]. Available from: https:\/\/publications.aap.org\/aapnews\/news\/17431\/First-oral-pan-genotypic-HCV-drugs-approved-for."},{"key":"10.1016\/bs.enz.2025.06.003_bib0075","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/v16030366","article-title":"Recent advances on targeting proteases for antiviral development","volume":"16","author":"Borges","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103799","article-title":"The expanding repertoire of covalent warheads for drug discovery","volume":"28","author":"Mehta","year":"2023","journal-title":"Drug Discovery Today"},{"key":"10.1016\/bs.enz.2025.06.003_bib0077","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.bmc.2010.01.044","article-title":"Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species","volume":"18","author":"Bogen","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0078","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2012.20.1.019","article-title":"Cyclic peptides as therapeutic agents and biochemical tools","volume":"20","author":"Joo","year":"2012","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/bs.enz.2025.06.003_bib0079","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic peptides as drug candidates: recent progress and remaining challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/bs.enz.2025.06.003_bib0080","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.1021\/acs.jmedchem.8b01985","article-title":"Structure-based macrocycle design in small-molecule drug discovery and simple metrics to identify opportunities for macrocyclization of small-molecule ligands","volume":"62","author":"Cummings","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.enz.2025.06.003_bib0082","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1021\/jm0494523","article-title":"A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease:\u2009 discovery of potent and specific tripeptide inhibitors","volume":"47","author":"Llin\u00e0s-Brunet","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0083","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/jm0342414","article-title":"Structure\u2212activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061","volume":"47","author":"Llin\u00e0s-Brunet","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0084","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/0192623311398276","article-title":"A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061","volume":"39","author":"Stoltz","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.enz.2025.06.003_bib0086","article-title":"In Vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/bs.enz.2025.06.003_bib0087","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Chung","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/bs.enz.2025.06.003_bib0088","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100994","article-title":"Real-world effectiveness of voxilaprevir\/velpatasvir\/sofosbuvir in patients following DAA failure","volume":"6","author":"Graf","year":"2024","journal-title":"JHEP Reports"},{"key":"10.1016\/bs.enz.2025.06.003_bib0090","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/jvh.13497","article-title":"Resistance-associated substitutions after sofosbuvir\/velpatasvir\/voxilaprevir triple therapy failure","volume":"28","author":"Garcia-Cehic","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/bs.enz.2025.06.003_bib0091","first-page":"242","article-title":"Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019","volume":"29","author":"Rossetti","year":"2021","journal-title":"Infez. Med."},{"key":"10.1016\/bs.enz.2025.06.003_bib0092","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/1566523221666210707142838","article-title":"Prevalence of naturally occurring resistance associated substitutions in NS3\/4aprotease inhibitors in Iranian HCV\/HIV infected patients","volume":"19","author":"Baesi","year":"2021","journal-title":"Curr. HIV Res."},{"key":"10.1016\/bs.enz.2025.06.003_bib0093","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0094","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1055\/a-1217-7669","article-title":"Sofosbuvir, Velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: results from the German hepatitis C-registry (DHC-R)","volume":"58","author":"Vermehren","year":"2020","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0096","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: from discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/bs.enz.2025.06.003_bib0097","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/v16081337","article-title":"Update on hepatitis C vaccine: results and challenges","volume":"16","author":"Garbuglia","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.003_bib0098","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, progress, and challenges to hepatitis C vaccine development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.enz.2025.06.003_bib0099","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-20","article-title":"Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3\/4A protease inhibitors","volume":"11","author":"Matthew","year":"2020","journal-title":"mBio"},{"key":"10.1016\/bs.enz.2025.06.003_bib0100","doi-asserted-by":"crossref","first-page":"16999","DOI":"10.1021\/acsomega.9b02491","article-title":"Discovery of new inhibitors of hepatitis C virus NS3\/4A protease and its D168A mutant","volume":"4","author":"Meewan","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/bs.enz.2025.06.003_bib0101","doi-asserted-by":"crossref","first-page":"14740","DOI":"10.1021\/acs.jmedchem.0c01296","article-title":"Discovery of BMS-986144, a third-generation, pan-genotype NS3\/4A protease inhibitor for the treatment of hepatitis C virus infection","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0102","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/acs.oprd.1c00315","article-title":"Development of the enabling route for a novel HCV NS3\/4A inhibitor, furaprevir","volume":"26","author":"Zhang","year":"2022","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/bs.enz.2025.06.003_bib0103","unstructured":"Z. Liu, G. Li, P. Zheng, Y. Liu, B. Luo, G. Zeng, Z. Chen, Q. Jin, Z. Lin, inventors; Dongguan Dongyangguang Pharmaceutical Co ltd, assignee. Hepatitis C virus protease inhibitors, Chinese patent 102020698 (2011)."},{"key":"10.1016\/bs.enz.2025.06.003_bib0104","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202401844","article-title":"Design of hepatitis C protease inhibitors based on knottin fold","volume":"9","author":"Talanova","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/bs.enz.2025.06.003_bib0107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.enz.2025.06.003_bib0108","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/acs.jmedchem.4c02068","article-title":"Targeted degradation of HCV polymerase by GalNAc-conjugated ApTACs for pan-genotypic antiviral therapy with high resistance barriers","volume":"68","author":"Pan","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.enz.2025.06.003_bib0109","first-page":"10","article-title":"Small molecule degraders of the hepatitis c virus protease reduce susceptibility to resistance mutations","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."}],"container-title":["The Enzymes","Viral Proteases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:54:24Z","timestamp":1768938864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604725000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443313967"],"references-count":107,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2025.06.003","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}